Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

Valneva phase 3 trial group, Rajeka Lazarus, Benedicte Querton, Irena Corbic Ramljak, Shailesh Dewasthaly, Juan Carlos Jaramillo, Katrin Dubischar, Michael Krammer, Petronela Weisova, Romana Hochreiter, Susanne Eder-Lingelbach, Christian Taucher*, Adam Finn

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology